Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 5, 2018. The document serves as a transaction notification regarding a specific executive compensation event rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate company financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It details a single transaction involving the vesting of a Deferred Investment Award Plan for a Principal Director or Manager (PDMR).
- Instrument: American Depositary Shares (ADSs) - ISIN: US37733W1053
- Transaction Type: Vesting of award made on March 2, 2015
- Volume: 18,967.031 notional ADSs
- Price: $36.10 per ADS
- Value: Gross cash payment of $684,709.84 (subject to tax withholding)
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses the settlement of a deferred compensation award for Mr. B McNamara, CEO of GSK Consumer Healthcare.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of a specific transaction date (March 2, 2018) and settlement details.
Investor Verification Points
- Verify the identity of the recipient: Mr. B McNamara, CEO of GSK Consumer Healthcare.
- Confirm the transaction date of March 2, 2018, and the filing date of March 5, 2018.
- Note that the gross value of $684,709.84 is subject to applicable tax withholding, meaning the net payout will be lower.
- Recognize that this filing does not reflect broader company performance metrics for the quarter or year.